{"id":"NCT00105443","sponsor":"Bayer","briefTitle":"A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma","officialTitle":"A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2005-03-15","resultsPosted":"2010-09-27","lastUpdate":"2014-10-31"},"enrollment":602,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"DRUG","name":"Sorafenib (Nexavar, BAY43-9006)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sorafenib (Nexavar, BAY43-9006)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics (PK) in patients with liver cancer.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"from randomization to death due to any cause until an average 7.2 months later up to the data cut-off date approximately 19 months after start of enrollment","effectByArm":[{"arm":"Sorafenib (Nexavar, BAY43-9006)","deltaMin":324,"sd":null},{"arm":"Placebo","deltaMin":241,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00583"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":178,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","Croatia","France","Germany","Greece","Israel","Italy","Mexico","New Zealand","Peru","Poland","Romania","Russia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["18650514","40388796","28687477"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":153,"n":297},"commonTop":["fatigue","diarrhea","pain, abdomen nos","anorexia","ascites"]}}